DAC vs No-DAC CJC-1295: Understanding the Albumin Binding Difference

Few topics in the peptide research community generate as much confusion as the distinction between CJC-1295 with DAC and CJC-1295 without DAC (often called Modified GRF 1-29). Despite sharing a name, these two peptides behave very differently in the body — differing in half-life, dosing frequency, GH release patterns, and practical research applications. The key to understanding this difference lies in a small molecular addition called the Drug Affinity Complex (DAC).

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates somatotroph cells in the anterior pituitary to produce and secrete growth hormone (GH). Native GHRH(1-44) is rapidly degraded in plasma by the enzyme dipeptidyl peptidase-IV (DPP-IV), giving it a biological half-life of less than 7 minutes.

To overcome this limitation, researchers at ConjuChem Biotechnologies developed a modified 29-amino-acid GHRH analog with four amino acid substitutions (at positions 2, 8, 15, and 27) that confer resistance to DPP-IV cleavage. This base peptide — known as Modified GRF (1-29) or tetrasubstituted GRF(1-29) — was first described in early structure-activity studies and extends the functional half-life to roughly 30 minutes (Iovino et al., 2012).

The critical innovation came when ConjuChem added a Drug Affinity Complex — a reactive lysine-linked maleimidopropionic acid moiety — to the C-terminus of this modified peptide. This DAC group forms a covalent bond with serum albumin after subcutaneous injection, creating a long-circulating bioconjugate. The result was CJC-1295 with DAC, a peptide with a dramatically extended half-life.

The Drug Affinity Complex: How Albumin Binding Changes Everything

The DAC technology exploits the long circulatory half-life of human serum albumin, which persists in plasma for approximately 19 days. When CJC-1295-DAC is injected, the maleimide group reacts with a free thiol (Cysteine-34) on circulating albumin within minutes, forming a stable thioether bond (Bhatt et al., 2014).

This albumin conjugation achieves several things simultaneously:

The landmark pharmacokinetic study by Teichman et al., 2006 demonstrated that a single subcutaneous injection of CJC-1295 with DAC produced dose-dependent increases in GH and IGF-1 that persisted for 6–14 days. Mean IGF-1 levels increased by 1.5 to 3-fold over baseline after repeated doses, with no significant desensitization observed over the study period. The estimated half-life of the albumin-bound conjugate was approximately 5.8–8.1 days.

Modified GRF (1-29): The "No-DAC" Variant

What the research community commonly calls "CJC-1295 without DAC" is technically Modified GRF (1-29) — the same tetrasubstituted GHRH analog, but without the albumin-binding moiety. It retains full agonist activity at the GHRH receptor but behaves like a conventional peptide in terms of pharmacokinetics.

Without albumin conjugation, Modified GRF (1-29) has an estimated half-life of approximately 30 minutes — vastly longer than native GHRH but nowhere near the multi-day duration of the DAC version (Alba et al., 2006). This means it produces an acute, pulsatile burst of GH release that more closely mimics the natural ultradian rhythm of GH secretion.

This distinction matters. Endogenous GH is released in pulsatile bursts approximately every 3–4 hours, with the largest pulse occurring during slow-wave sleep. Research suggests that the pulsatile pattern of GH release — not just the total amount — is important for downstream physiological effects, including lipolysis and hepatic IGF-1 production (Giustina & Veldhuis, 1998).

Pulsatile vs. Sustained GH Elevation: Why It Matters

This is where the DAC vs. no-DAC distinction becomes most scientifically interesting. The two peptides create fundamentally different GH secretion profiles:

Research in animal models has shown that continuous GH exposure and pulsatile GH exposure activate different gene expression profiles in the liver. Pulsatile GH preferentially activates the JAK2-STAT5b signaling pathway, which is critical for sexual dimorphism in hepatic gene expression and for optimal IGF-1 production (Waxman & O'Connor, 2006).

In a relevant clinical context, Ionescu & Bhatt, 2006 noted that while sustained GH-releasing compounds offer convenience, the blunting of natural pulsatility could theoretically lead to GH receptor downregulation over time — though this was not conclusively observed in the short-duration Teichman trial.

Synergy with GHRPs and Ghrelin Mimetics

Both variants of CJC-1295 are frequently studied in combination with growth hormone-releasing peptides (GHRPs) or ghrelin mimetics such as Ipamorelin or Hexarelin. GHRH and ghrelin act through separate receptors (GHRH-R and GHS-R1a, respectively) on somatotroph cells and produce a synergistic rather than merely additive GH release when co-administered (Bowers et al., 1990).

For Modified GRF (1-29), the pairing is straightforward: both peptides are administered simultaneously, producing a large, acute GH pulse. The GHRP component also suppresses somatostatin tone, further amplifying the GHRH signal.

For CJC-1295 with DAC, the combination is more complex. Because the DAC version provides continuous GHRH-receptor stimulation, adding a pulsatile GHRP theoretically provides periodic amplification on top of an elevated baseline. However, some researchers have raised concerns that chronic GHRH-receptor occupancy by the albumin-bound conjugate could partially desensitize the receptor, potentially reducing the magnitude of GHRP-synergized pulses over time (Veldhuis et al., 2012).

Safety Considerations in Research

The Teichman et al. study reported that CJC-1295 with DAC was generally well tolerated, with the most common adverse effects being injection site reactions, flushing, and transient headache. However, it is important to note that large-scale, long-term safety data for either variant remain limited.

Potential concerns that warrant further investigation include:

Neither peptide is currently approved by the FDA for any clinical indication. All references to dosing and effects should be understood within the context of preclinical and early-phase clinical research.

Practical Comparison at a Glance

Key Takeaways